Furthermore, considering that ECN can act as an immune adjuvant to recruit immune cells to infiltrate tumor sites, CD3+, CD4+, and CD8+ immune cells accumulate in the tumor microenvironment, reversing tumor immune suppression (Fig. 5) [41]. This evidence concerns the gene CD4 and neoplasm.